Biotech Stocks Facing FDA Decision In February 2024 : vimars

The year 2024 has begun on a muted note in terms of FDA approvals, with only one novel drug getting endorsed in January. Let's take a look at the biotech companies that are awaiting FDA word on their drug candidates in February.

Related Keywords

Canada , United States , Abbvie Humira , Minerva Neurosciences Inc , Iovance Biotherapeutics Inc , Minerva Neuroscience New Drug Application , Cancer , Pdufa , Eda Decision , Soil , Lifileucel , Scizophrenia ,